2024 Emergent biosolution stock - Emergent BioSolutions, which Mr. El-Hibri took public in 2006, bought up competitors in order to sell treatments for smallpox, botulism and other potential agents of germ warfare, becoming a prime ...

 
Track Emergent Biosolutions Inc (EBS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors. Emergent biosolution stock

Get the latest Emergent Biosolutions Inc (EBS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Dec 1, 2023 · According to the issued ratings of 2 analysts in the last year, the consensus rating for Emergent BioSolutions stock is Reduce based on the current 1 sell rating and 1 hold rating for EBS. The average twelve-month price prediction for Emergent BioSolutions is $15.50 with a high price target of $22.00 and a low price target of $9.00. Mar 29, 2023 · Emergent Biosolutions is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Exact Sciences (EXAS), a stock from the same industry, has gained 6.4%. Nov 7, 2013 · A high-level overview of Emergent BioSolutions Inc. (EBS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Emergent Biosolutions Inc Stock Price History. Emergent Biosolutions Inc’s price is currently down 8.49% so far this month. During the month of April, Emergent Biosolutions Inc’s stock price has reached a high of $13.67 and a low of $9.46. Over the last year, Emergent Biosolutions Inc has hit prices as high as $40.45 and as low as $7.74.Mar 29, 2023 6:24 AM PDT. By Will Feuer. Shares of Emergent BioSolutions Inc. rose after the U.S. Food and Drug Administration said the company's overdose reversal medication Narcan could be sold ...146.71. +1.95%. 40.54M. View today's Emergent Biosolutions Inc stock price and latest EBS news and analysis. Create real-time notifications to follow any changes in the live stock price.EBS US29089Q1058 Pharmaceuticals Summary Quotes Charts News Ratings Calendar Company Financials Consensus Revisions Funds and ETFs -40% on all our …Emergent stock has rallied from $50 to $130 off the recent bottom compared to the S&P which moved 50%, with resumption of economic activities as lockdowns are gradually lifted. Emergent stock is ...The company’s stock price dipped and shareholders sued Emergent, claiming they had been misled. ... Emergent Biosolutions, is having with the lack of clarity and transparency in CDC's ...Emergent Biosolutions stock is currently +15.47% from its 52-week low of $1.81, and -87.46% from its 52-week high of $16.66. As of Nov 20, 2023, there are 51.81M EBS shares outstanding. The market value of EBS is $108.28M. In the past 24 hours, 844,197 EBS shares were traded.Emergent Biosolutions is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Axsome Therapeutics (AXSM), a stock from the same industry, has gained 16.4%.Bought 1.3 Million shares of Emergent BioSolutions Inc: ... Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All ...Emergent BioSolutions. Reports Q1 2023 total revenues of $165M, above the prior guidance range, net loss of $183M and adjusted EBITDA of negative $101M. Updates FY 2023 guidance and provides ...Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results Expects a re-baseline of operations with stable revenue contributions from core products and services business in 2022, guiding to total revenues of $1.45 billion at the midpoint and Adjusted EBITDA margin of 21.5% at the midpointEmergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023. GAITHERSBURG, Md. , Oct. 19, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 2, 2023 , at 5:00 pm eastern time to discuss the financial results for the. Emergent BioSolutions. Market Cap. $108M. Today's Change. (%) Current Price. $2.09. Price as of November 24, 2023, 1:00 p.m. ET. You’re reading a free article with opinions that may differ from ...Emergent BioSolutions (EBS-6.98%) ended the week on a down note. Shares of the company closed 6.2% lower on Friday after it provided its fourth-quarter update following the market close on Thursday.Overview Stock Screener Earnings Calendar Sectors NYSE | EBS U.S.: NYSE Emergent Biosolutions Inc. Watch list Set a price target alert After Hours Last Updated: Nov 13, 2023 5:15 p.m. EST...Institutions' substantial holdings in Emergent BioSolutions implies that they have significant influence over the company's share price 50% of the business is held by the top 15 shareholders10 stocks we like better than Emergent BioSolutions When o ur award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley ...Feb 15, 2023 · Bavarian Nordic scoops up Emergent's travel vaccines, manufacturing site in deal worth up to $380M. After a tough third quarter in which Emergent BioSolutions cut more than $100 million from its ... Emergent BioSolutions. Market Cap. $108M. Today's Change. (%) Current Price. $2.09. Price as of November 24, 2023, 1:00 p.m. ET. You’re reading a free article with opinions that may differ from ...Emergent BioSolutions Inc. (NYSE:NYSE:EBS) Q1 2023 Earnings Conference Call May 9, 2023 5:00 PM ETCompany ParticipantsBob Burrows - VP, IRBob Kramer -...The ratio of current share price to trailing twelve month EPS that signals if the price is high or low compared to other stocks Dividend yield The ratio of annual dividend to current …8 thg 11, 2023 ... Emergent BioSolutions Inc. (NYSE: EBS) reported Q3 2023 total revenues of $271M, a pre-tax loss of $(266)M, and adjusted EBITDA of $20M. The ...Emergent Biosolutions Inc. analyst ratings, historical stock prices, ... Actuals & Estimates Emergent Biosolutions Inc. Quarterly; Annual; Actual Analyst Range Consensus. 2.00 …Emergent Biosolutions is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Axsome Therapeutics (AXSM), a stock from the same industry, has gained 16.4%.Emergent Biosolutions Inc Stock Price History. Emergent Biosolutions Inc’s price is currently up 3.96% so far this month. During the month of May, Emergent Biosolutions Inc’s stock price has reached a high of $10.88 and a low of $8.20. Over the last year, Emergent Biosolutions Inc has hit prices as high as $40.45 and as low as $7.74.Emergent BioSolutions, Inc. (EBS) CEO Robert Kramer on Q1 2021 Results - Earnings Call Transcript SA Transcripts Fri, Apr. 30, 2021 Emergent Biosolutions (EBS) Presents At KeyBanc Life Sciences ...Information on stock, financials, earnings, subsidiaries, investors, and executives for Emergent BioSolutions. Use the PitchBook Platform to explore the ...(NYSE:EBS) institutional owners may be pleased with recent gains after 83% loss over the ... Yahoo Finance. 3 weeks ago. Emergent BioSolutions ...Mar 10, 2023 · Emergent Biosolutions Inc Stock Price History. Emergent Biosolutions Inc’s price is currently down 21.73% so far this month. During the month of March, Emergent Biosolutions Inc’s stock price has reached a high of $12.54 and a low of $9.40. Over the last year, Emergent Biosolutions Inc has hit prices as high as $45.14 and as low as $10.14. Emergent Biosolutions stock has rallied 111% since late March (vs. about 53% for the S&P 500) to its current level around $105. The stock fell to a low of $50 in late March when a rapid increase ...Emergent Biosolutions (EBS) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of $0.32. This compares to earnings of $4.50 per share a year ago. These figures ...Find the latest Emergent BioSolutions Inc. (0IGA.L) stock quote, history, news and other vital information to help you with your stock trading and investing.Stock Quote & Chart. Data Provided by Refinitiv. Minimum 15 minutes delayed. The Investor Relations website contains information about Emergent BioSolutions Inc.'s business for stockholders, potential investors, and financial analysts.10 stocks we like better than Emergent BioSolutions When o ur analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock ...Get the latest Emergent Biosolutions Inc. (EBS) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.Emergent BioSolutions. Market Cap. $108M. Today's Change. (%) Current Price. $2.09. Price as of November 24, 2023, 1:00 p.m. ET. You’re reading a free article with opinions that may differ from ...Number of shares. Market capitalization. Please wait... News about Emergent Biosolutions Inc. ▻. No news available. Performance Emergent Biosolutions Inc.Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023. GAITHERSBURG, Md. , Oct. 19, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 2, 2023 , at 5:00 pm eastern time to discuss the financial results for the. Dec 1, 2023 · Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola. GAITHERSBURG, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a 10-year contract by the Biomedical Advanced ... See the latest Emergent BioSolutions Inc stock price (EBS:XNYS), related news, valuation, dividends and more to help you make your investing decisions.Revenue Metrics. Total revenues for 2022 are expected to be in the range of $1,100 million to $1,120 million, a decrease at the midpoint of $683 million or 38% as compared to 2021. Profitability ...Crypto Sectors Contact Us U.S. markets closed +13.44 -23.27 Russell 2000 +11.00 Emergent BioSolutions Inc. (EBS) NYSE - Nasdaq Real Time Price. Currency in USD Follow 2W 10W 9M 2.1500 +0.1400...Emergent BioSolutions Inc. Stock , EBS 2.39 + +% After-market 06:53:01 PM EDT 12/1/2023 NYSE Add to watchlist 2.39 +0.25 +11.68% Official Close 04:00:00 …Find the latest Emergent BioSolutions Inc. (EBS) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Emergent BioSolutions has seen a significant revenue decline and stock value drop within the past year. The FDA has approved Emergent's over-the-counter Narcan, a drug to treat opioid overdoses.View the latest Emergent Biosolutions Inc. (EBS) stock price, news, historical charts, analyst ratings and financial information from WSJ.Emergent Biosolutions Inc Stock Price History. Emergent Biosolutions Inc’s price is currently up 19.59% so far this month. During the month of April, Emergent Biosolutions Inc’s stock price has reached a high of $13.67 and a low of $9.47. Over the last year, Emergent Biosolutions Inc has hit prices as high as $43.33 and as low as $7.74.Emergent BioSolutions Inc EBS Morningstar Rating Unlock Stock XNYS Rating as of Nov 29, 2023 Summary Chart News Price vs Fair Value Sustainability …Emergent Biosolutions Inc Stock Price History. Emergent Biosolutions Inc’s price is currently down 37.08% so far this month. During the month of March, Emergent Biosolutions Inc’s stock price has reached a high of $12.54 and a low of $7.77. Over the last year, Emergent Biosolutions Inc has hit prices as high as $45.14 and as …Emergent Biosolutions (NYSE: EBS) is owned by 79.75% institutional shareholders, 93.92% Emergent Biosolutions insiders, and 0.00% retail investors. Fuad Elhibri is the largest individual Emergent Biosolutions shareholder, owning 25.73M shares representing 49.67% of the company. Fuad Elhibri's Emergent Biosolutions shares are currently …Emergent Biosolutions (NYSE: EBS) is owned by 79.75% institutional shareholders, 93.92% Emergent Biosolutions insiders, and 0.00% retail investors. Fuad Elhibri is the largest individual Emergent Biosolutions shareholder, owning 25.73M shares representing 49.67% of the company. Fuad Elhibri's Emergent Biosolutions shares are currently …Revenue Metrics. Total revenues for 2022 are expected to be in the range of $1,100 million to $1,120 million, a decrease at the midpoint of $683 million or 38% as compared to 2021. Profitability ...The closing price is not necessarily indicative of future price performance. Data Provided by Refinitiv. Minimum 15 minutes delayed. The Investor Relations website …Emergent Biosolutions stock has rallied 111% since late March (vs. about 53% for the S&P 500) to its current level around $105. The stock fell to a low of $50 in late March when a rapid increase ...GAITHERSBURG, Md., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced that it has entered into an agreement to sell its travel health business to Bavarian Nordic ...Emergent Biosolutions is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Exact Sciences (EXAS), a stock from the same industry, has gained 6.4%.The bid-ask spread can indicate a stock’s liquidity, which is how easy it is to buy and sell in theFeb 27, 2023 · Purchases of treasury stock (82.1) (106.0) Principal payments on convertible senior notes — (10.6) Proceeds from revolving credit facility 598.0 — Principal payments on term loan facility (33.8) (25.3) Proceeds from stock-based compensation activity 5.0 15.9 Taxes paid for stock-based compensation activity (5.9) (13.8) Contingent ... EBS Stock Overview. Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States.Emergent BioSolutions’ (NYSE:EBS) stock has spiked up over the past week as a monkeypox outbreak begins to spread in Europe and North America. Unlike with COVID-19 we already have approved ...Track Emergent Biosolutions Inc (EBS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsEmergent Biosolutions is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Exact Sciences (EXAS), a stock from the same industry, has gained 6.4%.Emergent BioSolutions has seen a significant revenue decline and stock value drop within the past year. The FDA has approved Emergent's over-the-counter Narcan, a drug to treat opioid overdoses.Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -8.16% and 59.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?Emergent Biosolutions belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Ultragenyx RARE , closed the last trading session 3.7% higher at $39.07.Earnings: 26-Feb (Est.) Company Event: 1-Jul. EBS Stock Summary and Trading Ideas (Emergent Biosolutions ...Revenue Metrics. Total revenues for 2022 are expected to be in the range of $1,100 million to $1,120 million, a decrease at the midpoint of $683 million or 38% as compared to 2021. Profitability ...N/A. N/A. See Emergent BioSolutions Inc. (EBS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.Stock Price Forecast. The 2 analysts offering 12-month price forecasts for Emergent BioSolutions Inc have a median target of 6.00, with a high estimate of 7.00 and a low estimate of 5.00. The ...2011. The Investor Relations website contains information about Emergent BioSolutions Inc.'s business for stockholders, potential investors, and financial analysts.10 stocks we like better than Emergent BioSolutions When o ur analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock ...The ratio of current share price to trailing twelve month EPS that signals if the price is high or low compared to other stocks Dividend yield The ratio of annual dividend to current …See the latest Emergent BioSolutions Inc stock price (EBS:XNYS), related news, valuation, dividends and more to help you make your investing decisions.Emergent Biosolutions is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Exact Sciences (EXAS), a stock from the same industry, has gained 6.4%.Emergent Biosolutions Inc Stock Price History. Emergent Biosolutions Inc’s price is currently up 27.51% so far this month. During the month of April, Emergent Biosolutions Inc’s stock price has reached a high of $13.67 and a low of $9.47. Over the last year, Emergent Biosolutions Inc has hit prices as high as $43.33 and as low as $7.74.Emergent Biosolutions (EBS) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2023. This widely-known consensus ...N/A. N/A. See Emergent BioSolutions Inc. (EBS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.The stock price of government contractor Emergent BioSolutions has fallen sharply since the disclosure at the end of March that production problems at the firm’s plant in Baltimore had ruined 15 ...26 thg 4, 2021 ... The chief executive of the pharmaceutical giant Emergent BioSolutions sold $10m in company stock weeks before the publication of the ...Emergent Biosolutions Inc. Watch list Set a price target alert After Hours Last Updated: Nov 13, 2023 5:15 p.m. EST Delayed quote $ 1.7600 -0.06 -3.30% After Hours Volume: …Shares of Emergent BioSolutions ( EBS) were soaring by 12.1% as of 10:34 a.m. ET on Thursday. The big gain came as concerns increased about a monkeypox outbreak in Europe. Monkeypox cases are also ...What are individual investors saying about Emergent BioSolutions? View the latest EBS social media trends at MarketBeat. Skip to main content. S&P 500 4,553.75 (-0.89%) DOW 36,095.50 (-0.41%) ... Stock Ideas and Recommendations. Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the …Key Points. Emergent BioSolutions saw its stock plummet due to a bunch of problems in 2021. Its pipeline is unimpressive, and its services revenue isn't anything special. If its sales of over-the ...Emergent Biosolutions Inc Stock Price History. Emergent Biosolutions Inc’s price is currently down 13.22% so far this month. During the month of April, Emergent Biosolutions Inc’s stock price has reached a high of $13.67 and a low of $8.92. Over the last year, Emergent Biosolutions Inc has hit prices as high as $40.45 and as low as $7.74.Apr 10, 2023 · Benchmark upgraded Emergent BioSolutions Inc (NYSE:EBS) from Hold To Buy with a price target of $22 on the positive FDA and Narcan market news.; Related: FDA Approves First OTC Naloxone Nasal ... Emergent biosolution stock

Emergent Biosolutions Inc Stock Price History. Emergent Biosolutions Inc’s price is currently up 19.5% so far this month. During the month of April, Emergent Biosolutions Inc’s stock price has reached a high of $12.56 and a low of $9.47. Over the last year, Emergent Biosolutions Inc has hit prices as high as $43.46 and as low as $7.74.. Emergent biosolution stock

emergent biosolution stock

Analyst Recommendations on Emergent BioSolutions Inc. Benchmark Downngrades Emergent Biosolutions to Hold From Buy. Aug. 29. MT. Benchmark Upgrades Emergent Biosolutions to Buy From Hold, Price Target is $22. Apr. 10. MT. JPMorgan Downgrades Emergent Biosolutions to Underweight From Neutral, Adjusts Price Target to $9 From $23.Tasos Katopodis. Contract manufacturer Emergent BioSolutions ( NYSE: EBS) fell ~3% in early pre-market trading Thursday after announcing its plans to sell $150M shares of common stock under an ...Emergent Biosolutions Inc Stock Price History. Emergent Biosolutions Inc’s price is currently up 19.5% so far this month. During the month of April, Emergent Biosolutions Inc’s stock price has reached a high of $12.56 and a low of $9.47. Over the last year, Emergent Biosolutions Inc has hit prices as high as $43.46 and as low as $7.74.Emergent Biosolutions Inc Stock Price History. Emergent Biosolutions Inc’s price is currently down 28.43% so far this month. During the month of March, Emergent Biosolutions Inc’s stock price has reached a high of $12.54 and a low of $7.74. Over the last year, Emergent Biosolutions Inc has hit prices as high as $45.14 and as low as $7.74.Reports Q1 2023 total revenues of $165M, above the prior guidance range, net loss of $183M and adjusted EBITDA of negative $101M. Updates FY 2023 guidance and provides initial Q2 2023 guidance. GAITHERSBURG, Md., May 09, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended ...Emergent BioSolutions Reports Financial Results for Fourth Quarter 2021. Reports Q4 2021 total revenues of $723M and Adjusted EBITDA of $348M resulting in FY 2021 total revenues of $1,793M and ...Track Emergent Biosolutions Inc (EBS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsA high-level overview of Emergent BioSolutions Inc. (EBS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.2011. The Investor Relations website contains information about Emergent BioSolutions Inc.'s business for stockholders, potential investors, and financial analysts.Reports Q1 2023 total revenues of $165M, above the prior guidance range, net loss of $183M and adjusted EBITDA of negative $101M. Updates FY 2023 guidance and provides initial Q2 2023 guidance. GAITHERSBURG, Md., May 09, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial …Reports Q1 2023 total revenues of $165M, above the prior guidance range, net loss of $183M and adjusted EBITDA of negative $101M. Updates FY 2023 guidance and provides initial Q2 2023 guidance. GAITHERSBURG, Md., May 09, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial …Historical daily share price chart and data for Emergent Biosolutions since 2006 adjusted for splits and dividends. The latest closing stock price for ...Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. [2] It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. May 9, 2023 · Reports Q1 2023 total revenues of $165M, above the prior guidance range, net loss of $183M and adjusted EBITDA of negative $101M. Updates FY 2023 guidance and provides initial Q2 2023 guidance. GAITHERSBURG, Md., May 09, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended ... Emergent BioSolutions Inc. shareholders can proceed in part with a lawsuit over sharp stock declines following news of contaminated Covid-19 vaccine batches at the company’s production facility and a canceled government contract, a federal court ruled. The investors plausibly alleged numerous intentional, material misrepresentations and ...Emergent Biosolutions belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Ultragenyx RARE , closed the last trading session 3.7% higher at $39.07.GAITHERSBURG, Md., May 15, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced it has completed the sale of its travel health business to Bavarian Nordic (OMX: BAVA). At ...Emergent Biosolutions Inc. historical stock charts and prices, analyst ratings, financials, and today’s real-time EBS stock price. Institutions' substantial holdings in Emergent BioSolutions implies that they have significant influence over the company's share price 50% of the business is held by the top 15 shareholdersThe closing price is not necessarily indicative of future price performance. Data Provided by Refinitiv. Minimum 15 minutes delayed. The Investor Relations website …Emergent Biosolutions is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Axsome Therapeutics (AXSM), a stock from the same industry, has gained 16.4%.Emergent Biosolutions Inc Stock Price History. Emergent Biosolutions Inc’s price is currently down 21.73% so far this month. During the month of March, Emergent Biosolutions Inc’s stock price has reached a high of $12.54 and a low of $9.40. Over the last year, Emergent Biosolutions Inc has hit prices as high as $45.14 and as low as $10.14.Emergent Biosolutions stock is currently +15.47% from its 52-week low of $1.81, and -87.46% from its 52-week high of $16.66. As of Nov 20, 2023, there are 51.81M EBS shares outstanding. The market value of EBS is $108.28M. In the past 24 hours, 844,197 EBS shares were traded.Mar 10, 2023 · Emergent Biosolutions Inc Stock Price History. Emergent Biosolutions Inc’s price is currently down 21.73% so far this month. During the month of March, Emergent Biosolutions Inc’s stock price has reached a high of $12.54 and a low of $9.40. Over the last year, Emergent Biosolutions Inc has hit prices as high as $45.14 and as low as $10.14. The Investor Relations website contains information about Emergent BioSolutions Inc.'s business for stockholders, potential investors, and financial analysts. Skip to main navigation ... and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date ...MORE: In wake of Emergent BioSolutions' vaccine problems, CEO's stock trades come into focus The recent cross-contamination at the Baltimore plant is not the first time Emergent has had to answer ...Emergent BioSolutions has seen a significant revenue decline and stock value drop within the past year. The FDA has approved Emergent's over-the-counter Narcan, a drug to treat opioid overdoses.Emergent Biosolutions belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Ultragenyx RARE , closed the last trading session 3.7% higher at $39.07.Key Points. Emergent BioSolutions saw its stock plummet due to a bunch of problems in 2021. Its pipeline is unimpressive, and its services revenue isn't anything special. If its sales of over-the ...Crypto Sectors Contact Us U.S. markets closed +13.44 -23.27 Russell 2000 +11.00 Emergent BioSolutions Inc. (EBS) NYSE - Nasdaq Real Time Price. Currency in USD Follow 2W 10W 9M 2.1500 +0.1400...Mar 30, 2023 · Shares of Emergent BioSolutions ( EBS) were soaring 11% higher as of 11:13 a.m. ET on Thursday. The big gain came after the Food and Drug Administration (FDA) approved the company's Narcan on ... Emergent BioSolutions reinstated with an Underweight at JPMorgan November 20, 2023TipRanks. Mixed Financial Outlook for Emergent Biosolutions: Strong Narcan Sales Offset by Lowered Guidance and ...Aug 22, 2023 · Shares of Emergent BioSolutions ( EBS 11.68%) were tumbling 10.6% lower as of 11:29 a.m. ET on Tuesday. The decline came after S&P Global 's S&P Dow Jones Indices announced that Advance Auto Parts ... Bavarian Nordic scoops up Emergent's travel vaccines, manufacturing site in deal worth up to $380M. After a tough third quarter in which Emergent BioSolutions cut more than $100 million from its ...Emergent BioSolutions Reports Financial Results for Fourth Quarter 2021. Reports Q4 2021 total revenues of $723M and Adjusted EBITDA of $348M resulting in FY 2021 total revenues of $1,793M and ...Emergent Biosolutions stock (NYSE:EBS) has rallied 111% since late March (vs. about 53% for the S&P 500) to its current level around $105. The stock fell to a low of $50 in late March when a rapid ...The stock of Emergent Biosolutions Inc (EBS) has seen a -5.48% decrease in the past week, with a -0.75% drop in the past month, and a -51.23% fall in the past quarter. The volatility ratio for the week is 6.73%, and the volatility levels for the past 30 days are at 9.69% for EBS. The simple moving average for the last 20 days is -6.54% for …The company’s stock price dipped and shareholders sued Emergent, claiming they had been misled. ... Emergent Biosolutions, is having with the lack of clarity and transparency in CDC's ...GAITHERSBURG, Md., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced that it has entered into an agreement to sell its travel health business to Bavarian Nordic ...Reports Q1 2023 total revenues of $165M, above the prior guidance range, net loss of $183M and adjusted EBITDA of negative $101M. Updates FY 2023 guidance and provides initial Q2 2023 guidance. GAITHERSBURG, Md., May 09, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial …Nov 27, 2023 · Complete Emergent Biosolutions Inc. stock information by Barron's. View real-time EBS stock price and news, along with industry-best analysis. Shares of Emergent BioSolutions ( EBS) were soaring 11% higher as of 11:13 a.m. ET on Thursday. The big gain came after the Food and Drug Administration (FDA) approved the company's Narcan on ...View the latest Emergent Biosolutions Inc. (EBS) stock price, news, historical charts, analyst ratings and financial information from WSJ.On average, analysts give Emergent Biosolutions Inc a Hold rating. The average price target is $28.4, which means analysts expect the stock to climb by 231.00% over the next twelve months. That average ranking earns Emergent Biosolutions Inc an Analyst Rating of 3, which is better than 3% of stocks based on data compiled by InvestorsObserver.Emergent Biosolutions (EBS) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2023. This widely-known consensus ...Emergent BioSolutions' stock has been hit with negative news in recent months. The company's future and valuation appear bright and strong, creating a buying opportunity.Nov 4, 2021 · Emergent BioSolutions ruined millions of doses of Covid-19 vaccines. Now its $600 million deal is canceled. Share full article. One of Emergent BioSolutions’ plants in Baltimore last April. 8 thg 11, 2023 ... Emergent BioSolutions Inc. (NYSE: EBS) reported Q3 2023 total revenues of $271M, a pre-tax loss of $(266)M, and adjusted EBITDA of $20M. The ...Find the latest Emergent BioSolutions Inc. (EBS) stock quote, history, news and other vital information to help you with your stock trading and investing.Benchmark upgraded Emergent BioSolutions Inc (NYSE:EBS) from Hold To Buy with a price target of $22 on the positive FDA and Narcan market news.; Related: FDA Approves First OTC Naloxone Nasal ...Bought 1.3 Million shares of Emergent BioSolutions Inc: ... Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All ...Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing. GAITHERSBURG, Md., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today confirmed that on November 16, 2023, the New York Stock Exchange (NYSE) sent a notice that the company is not in compliance with Section 802.01E of the NYSE Listed Company Manual due to a delay in filing its Quarterly ...Emergent Biosolutions is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Axsome Therapeutics (AXSM), a stock from the same industry, has gained 16.4%.Emergent BioSolutions’ (NYSE:EBS) stock has spiked up over the past week as a monkeypox outbreak begins to spread in Europe and North America. Unlike with COVID-19 we already have approved ...Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -8.16% and 59.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?View the latest Emergent Biosolutions Inc. (EBS) stock price, news, historical charts, analyst ratings and financial information from WSJ. Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. [2] It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Stock analysis for Emergent BioSolutions Inc (EBS:New York) including stock price, stock chart, company news, key statistics, fundamentals and company profile.2 equities research analysts have issued 12-month price targets for Emergent BioSolutions' shares. Their EBS share price targets range from $9.00 to $22.00. On average, they anticipate the company's share price to reach $15.50 in the next year. This suggests a possible upside of 638.1% from the stock's current price.. Options spreads